Fri, Aug 29, 2014, 1:23 AM EDT - U.S. Markets open in 8 hrs 7 mins

Recent

% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

bty79403 6 posts  |  Last Activity: Jun 26, 2014 6:34 AM Member since: Oct 23, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bty79403 by bty79403 Jun 26, 2014 6:34 AM Flag

    They're at it again. Let just hope that dumb takes dumber with him when he goes... Great products, but such poor, poor management, I can't describe how awful they are...

  • Reply to

    S-TECHNOLOGY CURVE

    by bluechiptool Jun 13, 2014 9:57 AM
    bty79403 bty79403 Jun 13, 2014 2:40 PM Flag

    There's over 400 hospitals in the UK alone, 1 per 125k people. The ablation market in Europe is several billion dollar, but that certainly doesn't mean that BSDM will get a large proportion of that. I pretty much switch off when he starts talking in billions! There is however a very good market opportunity, especially when you consider the minuscule enterprise value here.

    Cheers,
    Mick

    Sentiment: Strong Buy

  • Reply to

    S-TECHNOLOGY CURVE

    by bluechiptool Jun 13, 2014 9:57 AM
    bty79403 bty79403 Jun 13, 2014 2:02 PM Flag

    You can critisise Butch all you like, I probably have less respect for him than you. One thing he does have a perfect record in, is buying and selling BSDM stock.

    Sentiment: Strong Buy

  • Reply to

    S-TECHNOLOGY CURVE

    by bluechiptool Jun 13, 2014 9:57 AM
    bty79403 bty79403 Jun 13, 2014 11:22 AM Flag

    I can kind of understand when people didn't believe them, when they said that they expect to have a profitable quarter in fiscal 2014, (Q4 started about 2 weeks ago, and Q3 will report mid July). However, continuing to refuse to believe it, after they bought shares, is a recipe for crow pie.

    Whilst they can't buy on inside information, they're hardly likely to buy shares, and then miss on their publicly stated expectations!

    Cheers,
    Mick

    Sentiment: Strong Buy

  • Reply to

    This study.

    by bty79403 Jun 11, 2014 3:01 PM
    bty79403 bty79403 Jun 11, 2014 4:06 PM Flag

    Thanks for the down vote doc! nice to know you still care. Hope I haven't scared you? I wouldn't want you reporting me to Yahoo like you did to brj... I'm still shocked that you were scared of him, felt the need to clone him... So sad.

    Looks like I'm good for 20 in a row in our game, (every day it closes above a dollar you lose!!!). Go on, try one more time, they say third time is the charm, I'm waiting there. Tick tock, tick tock, it's Q4 now, profitability RIGHT NOW, tread carefully, you never know what's under foot....

    Much love,
    Mick

    Sentiment: Strong Buy

  • bty79403 by bty79403 Jun 11, 2014 3:01 PM Flag

    Let clear up a few things, this won't take 5 years, (neither will it take a month!), it will take 6 to 9 months to complete, and another 6 to 9 months to get published in a peer reviewed journal.

    This is a bridging study, and anyone who read my previous post would understand what's going on here. This system is approved, and proven in a clinical setting to ablate tumours that are out of the range of RFA by size. These are rare. There is a lot of pre-clinical work that suggests that SA-MA, doesn't suffer from the same problems as RFA when faced with heat sinks, (usually caused by vasculature). There is also a large weight of hearsay evidence to supplement these pre-clinical studies. You need to look at this from the point of view of the IR's and IO's. They either already have one of these machines that they use infrequently, or they would like one and can't justify having one on projected usage. It's perfectly valid that they would ask for a bridging study to validate in a clinical setting, the large pre-clinical and hearsay evidence. Don't get me wrong, IR's and IO's can use these where ever they like, (and some do), but it's valid to ask for this study.

    Taking the re-ablation market is huge, and there is no shortage of push back against this little company when trying to take that market, this study can mitigate that. Around one in two of every liver cancer patient that has RFA, would need future ablations. Physicians don't like telling patients that they are going to do the exact same procedure on them that has just failed! They want to use this product, some just need a little justification.

    Cheers,
    Mick

    Sentiment: Strong Buy

CLSN
3.23-0.01(-0.31%)Aug 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.